Cargando…
Engagement of monocytes, NK cells, and CD4(+) Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIV(mac251) vaginal acquisition
The recombinant Canarypox ALVAC-HIV/gp120/alum vaccine regimen was the first to significantly decrease the risk of HIV acquisition in humans, with equal effectiveness in both males and females. Similarly, an equivalent SIV-based ALVAC vaccine regimen decreased the risk of virus acquisition in Indian...
Autores principales: | Gorini, Giacomo, Fourati, Slim, Vaccari, Monica, Rahman, Mohammad Arif, Gordon, Shari N., Brown, Dallas R., Law, Lynn, Chang, Jean, Green, Richard, Barrenäs, Fredrik, Liyanage, Namal P. M., Doster, Melvin N., Schifanella, Luca, Bissa, Massimiliano, Silva de Castro, Isabela, Washington-Parks, Robyn, Galli, Veronica, Fuller, Deborah H., Santra, Sampa, Agy, Michael, Pal, Ranajit, Palermo, Robert E., Tomaras, Georgia D., Shen, Xiaoying, LaBranche, Celia C., Montefiori, David C., Venzon, David J., Trinh, Hung V., Rao, Mangala, Gale, Michael, Sekaly, Rafick P., Franchini, Genoveffa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093029/ https://www.ncbi.nlm.nih.gov/pubmed/32163525 http://dx.doi.org/10.1371/journal.ppat.1008377 |
Ejemplares similares
-
Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIV(mac251) Rectal Challenge
por: Tuero, Iskra, et al.
Publicado: (2015) -
Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIV(mac251) acquisition in macaques
por: Rahman, Mohammad Arif, et al.
Publicado: (2023) -
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2019) -
Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate
por: Vaccari, Monica, et al.
Publicado: (2019) -
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type
por: Schifanella, Luca, et al.
Publicado: (2020)